[go: up one dir, main page]

MX2013011231A - Nanoparticulas basadas en lipidos. - Google Patents

Nanoparticulas basadas en lipidos.

Info

Publication number
MX2013011231A
MX2013011231A MX2013011231A MX2013011231A MX2013011231A MX 2013011231 A MX2013011231 A MX 2013011231A MX 2013011231 A MX2013011231 A MX 2013011231A MX 2013011231 A MX2013011231 A MX 2013011231A MX 2013011231 A MX2013011231 A MX 2013011231A
Authority
MX
Mexico
Prior art keywords
compositions
lipid
based nanoparticles
amyloid
liposomal
Prior art date
Application number
MX2013011231A
Other languages
English (en)
Other versions
MX357227B (es
Inventor
Ananth Annapragada
Jason L Eriksen
Eric A Tanifum
Indrani Dasgupta
Stephen C Cook
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46966277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013011231(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2013011231A publication Critical patent/MX2013011231A/es
Publication of MX357227B publication Critical patent/MX357227B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan composiciones de nanopartículas basadas en lípidos. Las composiciones generalmente comprenden conjugados de ligando de unión a amiloide con polímero hidrofílico y lípido, y pueden ser composiciones liposómicas. Las composiciones, incluyendo las composiciones liposómicas, pueden ser útiles para la formación de Imágenes y para el tratamiento de los depósitos de la placa ß-amiloide característicos de la Enfermedad de Alzheimer.
MX2013011231A 2011-04-06 2012-04-06 Nanoparticulas basadas en lipidos. MX357227B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472605P 2011-04-06 2011-04-06
PCT/US2012/032649 WO2012139080A2 (en) 2011-04-06 2012-04-06 Lipid-based nanoparticles

Publications (2)

Publication Number Publication Date
MX2013011231A true MX2013011231A (es) 2015-03-05
MX357227B MX357227B (es) 2018-07-02

Family

ID=46966277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011231A MX357227B (es) 2011-04-06 2012-04-06 Nanoparticulas basadas en lipidos.

Country Status (14)

Country Link
US (1) US9801957B2 (es)
EP (2) EP2694116B1 (es)
JP (3) JP6212032B2 (es)
KR (2) KR102035187B1 (es)
CN (1) CN104144708B (es)
AU (3) AU2012239888B9 (es)
BR (1) BR112013025633A2 (es)
CA (1) CA2831480C (es)
DK (1) DK2694116T3 (es)
ES (1) ES2685824T3 (es)
MX (1) MX357227B (es)
PL (1) PL2694116T3 (es)
PT (1) PT2694116T (es)
WO (1) WO2012139080A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012139080A2 (en) * 2011-04-06 2012-10-11 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
ES2855165T3 (es) 2012-01-20 2021-09-23 Ananth Annapragada Métodos y composiciones para caracterizar objetivamente imágenes médicas
US9512092B2 (en) * 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
WO2016057812A1 (en) * 2014-10-08 2016-04-14 Texas Children's Hosptial Mri imaging of amyloid plaque using liposomes
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
CN109414451B (zh) * 2016-05-16 2022-08-12 德克萨斯大学系统董事会 用于作为纳米粒递送tRNA的组合物及其使用方法
US11241510B2 (en) 2016-11-30 2022-02-08 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19F MRI probes with unique MR signatures
EP3914230A4 (en) * 2019-01-24 2023-06-07 Alzeca Biosciences, Llc <SMALLCAPS/>? ? ?FUNCTIONALIZED LIPOSOMES FOR IMAGE MISFOLDED PROTEINS
CN115916263A (zh) * 2020-01-29 2023-04-04 德克萨斯儿童医院 用于淀粉样蛋白沉积mri的靶向对比剂
EP4103239A4 (en) * 2020-02-12 2024-03-20 Texas Children's Hospital TARGETED CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING OF ALPHA-SYNUCLEIN DEPOSITS
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331751A (en) * 1980-11-17 1982-05-25 Eastman Kodak Company Electrically photosensitive materials and elements for photoelectrophoretic imaging processes
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
CA2185810A1 (en) 1994-03-28 1995-10-05 Jo Klaveness Liposomes
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
US6989153B2 (en) 1999-11-30 2006-01-24 Varian Medical Systems Technologies, Inc. Radiation sensitive liposomes
US7029655B2 (en) 2000-10-04 2006-04-18 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US6821504B2 (en) * 2001-05-23 2004-11-23 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
EP1480691A4 (en) 2002-03-05 2007-11-28 Univ State Cleveland AGGLOMERATED PARTICLES FOR THE DISPOSAL OF A MEDICINAL PRODUCT IN AEROSOL FORM
US7605182B2 (en) 2003-05-01 2009-10-20 Aposense Ltd. Compounds that selectively bind to membranes of apoptotic cells
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
WO2006026184A2 (en) * 2004-08-20 2006-03-09 Washington University Blood brain barrier permeation peptides
JP2008513533A (ja) * 2004-09-23 2008-05-01 ゲルベ Ｃｅｓｔイメージング用の造影剤封入システム
WO2006126208A2 (en) * 2005-05-26 2006-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20100062969A1 (en) * 2006-04-07 2010-03-11 Hayat Onyuksel Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
WO2009015397A1 (en) 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
WO2009073236A1 (en) 2007-12-05 2009-06-11 Marval Biosciences, Inc. Nano-scale contrast agents and methods of use
US20100286067A1 (en) 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
ITMI20081052A1 (it) * 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
AU2009257279A1 (en) * 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
US20110208064A1 (en) 2008-07-31 2011-08-25 Ran Chongzhao Curcumin Derivatives for Amyloid-Beta Plaque Imaging
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CA2755998A1 (en) * 2009-03-19 2010-09-23 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
WO2010115080A2 (en) * 2009-04-02 2010-10-07 The Johns Hopkins University Self-assembling peptides bearing organic electronic functionality and applications employing the same
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
JP5746334B2 (ja) 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド Ｇｐｒ１２０受容体作動薬及びその使用
EP2680822B1 (en) 2011-03-02 2022-02-23 Sensulin, LLC Vesicle compositions
WO2012139080A2 (en) 2011-04-06 2012-10-11 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
ES2855165T3 (es) 2012-01-20 2021-09-23 Ananth Annapragada Métodos y composiciones para caracterizar objetivamente imágenes médicas
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
CA2906035A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
WO2016057812A1 (en) 2014-10-08 2016-04-14 Texas Children's Hosptial Mri imaging of amyloid plaque using liposomes

Also Published As

Publication number Publication date
US9801957B2 (en) 2017-10-31
AU2012239888A1 (en) 2013-11-07
JP6533813B2 (ja) 2019-06-19
PL2694116T3 (pl) 2018-12-31
AU2012239888B2 (en) 2017-06-22
EP3366313A1 (en) 2018-08-29
BR112013025633A2 (pt) 2017-08-08
JP2019151664A (ja) 2019-09-12
EP2694116A2 (en) 2014-02-12
CN104144708B (zh) 2017-07-28
PT2694116T (pt) 2018-10-12
KR20140074868A (ko) 2014-06-18
KR20190031334A (ko) 2019-03-25
EP2694116B1 (en) 2018-06-13
AU2012239888B9 (en) 2017-10-12
EP2694116A4 (en) 2015-06-03
AU2017232156A1 (en) 2017-10-12
DK2694116T3 (en) 2018-09-03
CN104144708A (zh) 2014-11-12
WO2012139080A2 (en) 2012-10-11
MX357227B (es) 2018-07-02
AU2017232156C1 (en) 2019-10-24
KR102035187B1 (ko) 2019-11-08
CA2831480C (en) 2020-09-29
WO2012139080A3 (en) 2014-05-01
AU2019246775A1 (en) 2019-10-31
AU2017232156B2 (en) 2019-07-11
JP2014523854A (ja) 2014-09-18
AU2012239888A2 (en) 2014-05-08
ES2685824T3 (es) 2018-10-11
JP2018035167A (ja) 2018-03-08
CA2831480A1 (en) 2012-10-11
HK1203827A1 (en) 2015-11-06
JP6212032B2 (ja) 2017-10-18
US20120258044A1 (en) 2012-10-11
KR101973063B1 (ko) 2019-04-30

Similar Documents

Publication Publication Date Title
MX357227B (es) Nanoparticulas basadas en lipidos.
IL245889A0 (en) Sulfonamide derivatives as bcl-2-selective apoptosis inducers for the treatment of cancer and immune diseases
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
EP2707369A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER&#39;S DISEASE
CA2865011C (en) Methods and compositions for treating huntington&#39;s disease
MX340055B (es) Metodos y composiciones de nanoparticulas sin priones.
MY188911A (en) Methods of treating bladder cancer
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
MX2017004695A (es) Formación de imágenes por irm de placas amiloides usando liposomas.
SG11201403272YA (en) Compositions and methods for treating alzheimer&#39;s disease
IL220974A0 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
WO2010105035A9 (en) Prevention, treatment, and diagnosis of alzheimer&#39;s disease through electromagnetic field exposure
WO2012040331A3 (en) Multistage nanoparticles
HK1215391A1 (zh) 使用胎盘细胞外基质治疗口腔病变
ZA201209452B (en) Gold complexes for use in the treatment of cancer
PL2331092T3 (pl) Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu
EP2693877A4 (en) METHODS AND COMPOSITIONS FOR TREATING RAYNAUD&#39;S DISEASE
WO2012151577A3 (en) Techniques to increase r1 in nanoparticle contrast agents for mri
WO2012153253A3 (en) Aromatic compounds and metal complexes thereof
EP2459194A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PARKINSON
ZA201402477B (en) Compounds for use in the treatment of alzheimer&#39;s disease

Legal Events

Date Code Title Description
FG Grant or registration